16:37 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest inhibiting signaling between RTN4R , RTN4RL2 and their ligands could help treat white matter stroke. In a mouse model of the disease, white matter levels of three negative regulators of...
07:00 , Sep 27, 2010 |  BioCentury  |  Emerging Company Profile

Axerion: Going beyond NOGO

While several companies are working on approaches to stimulating axonal regrowth for conditions caused or characterized by nerve damage, Axerion Therapeutics Inc. believes its NGR receptor decoys will more potently treat conditions such as acute...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 (RTN4; NOGO-A; NOGO); myelin-associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP); reticulon 4 receptor (RTN4R; NGR) In vitro and...
08:00 , Dec 4, 2008 |  BC Innovations  |  Cover Story

New strategies for CNS regeneration

Two separate teams of company and university researchers have identified multiple neuronal proteins that could be targeted alone or in combination to promote axon growth and treat spinal cord injury and other forms of CNS...